The discovery of first-in-class drugs: origins and evolution

Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines

(2013) D C Swinney   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phenotypic screens as a renewed approach for drug discovery

(2013) Wei Zheng et al.   DRUG DISCOVERY TODAY

Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it

(2013) Douglas B. Kell   FEBS Journal

Flupirtine, a re-discovered drug, revisited

(2013) Istvan Szelenyi   INFLAMMATION RESEARCH

Phenotypic Screening Strategies for Neurodegenerative Diseases: A Pathway to Discover Novel Drug Candidates and Potential Disease Targets or Mechanisms

(2012) R. M. Pruss   CNS & Neurological Disorders-Drug Targets

Back to the Future: Lessons Learned in Modern Target-based and Whole-Cell Lead Optimization of Antimalarials

(2012) Arnab K. Chatterjee et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Combining imaging and pathway profiling: an alternative approach to cancer drug discovery

(2012) Neil O. Carragher et al.   DRUG DISCOVERY TODAY

Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift

(2012) Frank Sams-Dodd   DRUG DISCOVERY TODAY

Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy

(2012) Jonathan A. Lee et al.   JOURNAL OF MEDICINAL CHEMISTRY

Forward Chemical Genetics in Yeast for Discovery of Chemical Probes Targeting Metabolism

(2012) Robert St.Onge et al.   MOLECULES

Diagnosing the decline in pharmaceutical R&D efficiency

(2012) Jack W. Scannell et al.   NATURE REVIEWS DRUG DISCOVERY

Protein Reporter Bioassay Systems for the Phenotypic Screening of Candidate Drugs: A Mouse Platform for Anti-Aging Drug Screening

(2012) Takuya Chiba et al.   SENSORS

How were new medicines discovered?

(2011) David C. Swinney et al.   NATURE REVIEWS DRUG DISCOVERY

The productivity crisis in pharmaceutical R&D

(2011) Fabio Pammolli et al.   NATURE REVIEWS DRUG DISCOVERY

Impact of high-throughput screening in biomedical research

(2011) Ricardo Macarron et al.   NATURE REVIEWS DRUG DISCOVERY

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Selective inhibition of BET bromodomains

(2010) Panagis Filippakopoulos et al.   NATURE

The case for entrepreneurship in R&D in the pharmaceutical industry

(2010) Frank L. Douglas et al.   NATURE REVIEWS DRUG DISCOVERY

Spiroindolones, a Potent Compound Class for the Treatment of Malaria

(2010) M. Rottmann et al.   SCIENCE

Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy

(2009) Matthew E.R. Butchbach et al.   HUMAN MOLECULAR GENETICS

Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer

(2009) Baozhi Chen et al.   Nature Chemical Biology

Pharmaceutical R&D: the road to positive returns

(2009) Eric David et al.   NATURE REVIEWS DRUG DISCOVERY

Lessons from 60 years of pharmaceutical innovation

(2009) Bernard Munos   NATURE REVIEWS DRUG DISCOVERY

A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: Advantages of pathway-based discovery

(2007) Marc K. Hellerstein   METABOLIC ENGINEERING